Illumina Inc Hits 20-Day High Following Upgrade
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: SeekingAlpha
Illumina Inc's stock rose by 4.13%, reaching a 20-day high amid positive market conditions.
The recent upgrade to a Zacks Rank #1 (Strong Buy) reflects a favorable earnings outlook, with analysts raising their earnings estimates by 4.5% over the past three months. This upgrade positions Illumina well for potential market-beating returns.
As the company navigates challenges in the biotech sector, this positive sentiment from analysts could attract more investors, potentially leading to further stock price appreciation.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 124.12 USD with a low forecast of 40.50 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
